For PDF Fillable Requisitions, the following applies:

- 1. The form shall be completed using a Digital Health assigned computer.
- 2. Absolutely no personal health information shall be electronically saved on a computer.
- 3. The completed form shall not be shared electronically. If you reasonably believe that e-mailing the information is the only available method of communication or the only way to send the information then you must adhere to the Privacy guideline titled "E-mailing Personal Health Information".
- 4. All forms must be completed in their entirety, e.g. if a staff member has only completed half of a form they cannot save their work and then come back to complete it at a later date.
- 5. Once the personal health information has been recorded onto the form, it is to be printed immediately, deleted (not saved) from the computer, and then stored securely inside the client (paper) health record or scanned into an electronic record.
- 6. Do not print unnecessary duplicate copies of the form.
- 7. Regular audits of the Digital Health assigned computer shall be undertaken to ensure that no personal health information is being duplicated and saved.

MOLECULAR HEMATOPATHOLOGY TEST REQUISITION

Acceptance Policy 10-50-03 - Requirements for Test Requisitions 2.1 - Fields marked with * are mandatory and must be clearly legible. Failure to comply may result in specimen rejection.

*** PIFASE COMPLETE THE INFORMATION RELOW. PRINT CLEARLY. CHECK APPROPRIATE PROFILE ***

ORDERING PROVIDER INFORMATION					PATIENT INFORMATION					
*Last & Full First Name:			ng Code:	*La	*Last/First Name: (per MB. Health Card)					
*Ordering			atient		* Date of Birth					
Facility:			ation:		(dd/mm/yyyy)					
Address:					*Sex: Female Male					
Critical Results Fax No: Phone Number:			No:	*Pl	*PHIN:					
Physician Signature:			ne No:	Spe	Specify if other province or DND					
COPY REPORT TO: (if info missing, report may not be sent)				MF	MRN:					
Last & Full First Name: Fax No:			No:	End	Encounter Number:					
Facility Name/Address:			ne No:	Pat	Patient Phone No:					
Last & Full First Name:			No:	Pat	Patient Address:					
Facility Name/Address:			ne No:	Der	Demographics verified with: ☐ Prov. Health Card ☐ Armband ☐ eChart/CR					
COLLECTION INFORMATION (fields marked with ◆ required by person collecting sample)										
♦ Collector:			◆ Collection Dat			♦ Collected Via:	□ Venipuncture□ Indwelling Line□ Above shu			
♦ Collection Facility/Lab:			◆ Collection Tim		l C I	☐ Capillary		IL OIL IA		
	# Serum vial(s) # Plasma vials (p) Referring I						Samples shipped frozen			
	mple Type	cal History								
☐ Peripheral Blood ☐ Bone Marrow										
	Formalin-fixed Paraffin-embedded Ca	se #:								
	Fresh/Frozen Tissue									
	Other									
				CODE	Previous Testing					
	Factor V Leiden and Prothrombin G20210A Mutation Hypercoagulability/Thrombophilia (diagnostic)			MOL						
					Other Testing Requirement					
	B Cell Clonality, Immunoglobulin Gene Rearrangement B cell lymphoma (diagnostic)			HMD						
	T Cell Clonality, T Cell Receptor Gene Rearrangement T cell lymphoma (diagnostic)			HMD	REFERRED OUT TEST NAME & PURPOSE SITE CODE					
	BCR/ABL1 Diagnostic Screen (non-quantitative) t(9;22)				ABL1 Tyrosine Kinase Inhibitor Resistance Screen			0002		
Ш	Philadelphia Chromosome CML, ALL (diagnostic)			HMD	CML, ALL (prognostic)					
	BCR/ABL1 Quantitative Monitoring, RQ BCR/ABL1 CML, ALL (follow-up)			HMD		CEBPA Mutation Testing AML (diagnostic) Mayo			HMD	
	PML/RARA Diagnostic Screen (non-quantitative), t(15;17) APL (diagnostic and follow-up)			HMD		□ CALR Myeloproliferative Neoplasm (MPN) Mayo HMC			HMD	
	RUNX1/RUNX1T1 (AML1/ETO) Rearrangement, t(8;21) AML (diagnostic)			HMD		Myeloid NGS Panel AML (diagnostic)			HMD	
	CBFB/MYH11 Rearrangement, inv(16), t(16;16) AML (diagnostic)			HMD		<u> </u>				
	ETV6/RUNX1 (TEL/AML1) Rearrangement, t(12;21) ALL (diagnostic)			HMD	Applicable Regional Health Authority. Submit samples and completed requisition to: K2 Shared Health Molecular Hematopathology Laboratory Health Sciences Centre MS559-820 Sherbrook Street					
	JAK2 V617F Mutation (quantitative) Myeloproliferative neoplasm (diagnostic)			JAK2						
	FLT3/NPM1 AML (diagnostic)			HMD						
	C-KIT Sequencing Analysis Mastocytosis/AML (diagnostic)									

